Cyclo Therapeutics Stock Working Capital

CYTHW Stock

USD 0.13 0 1.54%

Cyclo Therapeutics fundamentals help investors to digest information that contributes to Cyclo Therapeutics' financial success or failures. It also enables traders to predict the movement of Cyclo Stock. The fundamental analysis module provides a way to measure Cyclo Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cyclo Therapeutics stock.

	Last Reported	Projected for Next Year
Net Working Capital	3.9 M	5.2 M
Change In Working Capital	3.1 M	3.2 M

Net Working Capital is likely to climb to about 5.2 M in 2024. Change In Working Capital is likely to climb to about 3.2 M in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Cyclo Therapeutics Company Working Capital Analysis

Cyclo Therapeutics' Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Working Capital

Current Assets

-

Current Liabilities

More About Working Capital | All Equity Analysis

Current Cyclo Therapeutics Working Capital

3.85 M

Most of Cyclo Therapeutics' fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cyclo Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Cyclo Working Capital Driver Correlations

Understanding the fundamental principles of building solid financial models for Cyclo Therapeutics is extremely important. It helps to project a fair market value of Cyclo Stock properly, considering its historical fundamentals such as Working Capital. Since Cyclo Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cyclo Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cyclo Therapeutics' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Short Term Investments	Current Deferred Revenue	Capital Surpluse	Property Plant Equipment	Net Invested Capital	Net Working Capital	Capital Stock	Long Term Debt	Short Long Term Debt	Net Tangible Assets
Total Assets		0.85	-0.96	-0.71	0.81	0.68	0.73	0.99	0.4	-0.28	-0.42	-0.3	-0.52	0.8	0.7	0.91	0.9	-0.79	-0.67	0.65	-0.48
Total Stockholder Equity	0.85		-0.89	-0.3	0.45	0.79	0.28	0.84	-0.04	-0.23	-0.43	-0.23	-0.33	0.45	0.53	0.95	0.95	-0.65	-0.39	0.3	0.01
Net Debt	-0.96	-0.89		0.63	-0.79	-0.74	-0.62	-0.98	-0.22	0.2	0.37	0.22	0.63	-0.73	-0.72	-0.96	-0.95	0.77	0.58	-0.53	0.32
Retained Earnings	-0.71	-0.3	0.63		-0.91	-0.3	-0.94	-0.74	-0.82	0.24	0.29	0.28	0.7	-0.98	-0.65	-0.46	-0.44	0.77	0.89	-0.92	0.72
Accounts Payable	0.81	0.45	-0.79	-0.91		0.44	0.93	0.85	0.58	-0.24	-0.13	-0.27	-0.76	0.91	0.76	0.61	0.59	-0.67	-0.71	0.75	-0.67
Net Receivables	0.68	0.79	-0.74	-0.3	0.44		0.23	0.7	-0.14	-0.25	-0.07	-0.25	-0.46	0.41	0.31	0.79	0.8	-0.38	-0.45	0.31	0.03
Total Liab	0.73	0.28	-0.62	-0.94	0.93	0.23		0.73	0.79	-0.23	-0.21	-0.28	-0.55	0.91	0.63	0.44	0.42	-0.63	-0.76	0.86	-0.85
Total Current Assets	0.99	0.84	-0.98	-0.74	0.85	0.7	0.73		0.38	-0.24	-0.39	-0.26	-0.63	0.83	0.73	0.92	0.91	-0.81	-0.68	0.65	-0.46
Short Term Debt	0.4	-0.04	-0.22	-0.82	0.58	-0.14	0.79	0.38		-0.18	-0.29	-0.22	-0.28	0.76	0.34	0.05	0.02	-0.54	-0.75	0.82	-0.77
Intangible Assets	-0.28	-0.23	0.2	0.24	-0.24	-0.25	-0.23	-0.24	-0.18		-0.33	0.99	0.34	-0.21	-0.18	-0.13	-0.13	0.17	0.18	-0.18	0.08
Common Stock	-0.42	-0.43	0.37	0.29	-0.13	-0.07	-0.21	-0.39	-0.29	-0.33		-0.31	-0.08	-0.41	-0.3	-0.48	-0.48	0.71	0.45	-0.38	0.12
Short Term Investments	-0.3	-0.23	0.22	0.28	-0.27	-0.25	-0.28	-0.26	-0.22	0.99	-0.31		0.35	-0.24	-0.21	-0.13	-0.12	0.19	0.22	-0.25	0.1
Current Deferred Revenue	-0.52	-0.33	0.63	0.7	-0.76	-0.46	-0.55	-0.63	-0.28	0.34	-0.08	0.35		-0.68	-0.58	-0.46	-0.46	0.57	0.54	-0.49	0.27
Capital Surpluse	0.8	0.45	-0.73	-0.98	0.91	0.41	0.91	0.83	0.76	-0.21	-0.41	-0.24	-0.68		0.69	0.6	0.58	-0.85	-0.91	0.89	-0.66
Property Plant Equipment	0.7	0.53	-0.72	-0.65	0.76	0.31	0.63	0.73	0.34	-0.18	-0.3	-0.21	-0.58	0.69		0.61	0.6	-0.68	-0.46	0.46	-0.26
Net Invested Capital	0.91	0.95	-0.96	-0.46	0.61	0.79	0.44	0.92	0.05	-0.13	-0.48	-0.13	-0.46	0.6	0.61		1.0	-0.73	-0.49	0.4	-0.18
Net Working Capital	0.9	0.95	-0.95	-0.44	0.59	0.8	0.42	0.91	0.02	-0.13	-0.48	-0.12	-0.46	0.58	0.6	1.0		-0.72	-0.48	0.38	-0.15
Capital Stock	-0.79	-0.65	0.77	0.77	-0.67	-0.38	-0.63	-0.81	-0.54	0.17	0.71	0.19	0.57	-0.85	-0.68	-0.73	-0.72		0.78	-0.69	0.35
Long Term Debt	-0.67	-0.39	0.58	0.89	-0.71	-0.45	-0.76	-0.68	-0.75	0.18	0.45	0.22	0.54	-0.91	-0.46	-0.49	-0.48	0.78		-0.95	0.51
Short Long Term Debt	0.65	0.3	-0.53	-0.92	0.75	0.31	0.86	0.65	0.82	-0.18	-0.38	-0.25	-0.49	0.89	0.46	0.4	0.38	-0.69	-0.95		-0.66
Net Tangible Assets	-0.48	0.01	0.32	0.72	-0.67	0.03	-0.85	-0.46	-0.77	0.08	0.12	0.1	0.27	-0.66	-0.26	-0.18	-0.15	0.35	0.51	-0.66

Click cells to compare fundamentals

Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.

Competition

Predict Cyclo Therapeutics

Working Capital Over Time

Cyclo Capital Surpluse

Capital Surpluse

77.92 Million

At this time, Cyclo Therapeutics' Capital Surpluse is fairly stable compared to the past year.

In accordance with the company's disclosures, Cyclo Therapeutics has a Working Capital of 3.85 M. This is much higher than that of the Biotechnology sector and significantly higher than that of the Health Care industry. The working capital for all United States stocks is notably lower than that of the firm.

Cyclo Working Capital Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cyclo Therapeutics' direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cyclo Therapeutics could also be used in its relative valuation, which is a method of valuing Cyclo Therapeutics by comparing valuation metrics of similar companies.

Cyclo Therapeutics is currently under evaluation in working capital category among its peers.

Cyclo Fundamentals

	Return On Equity	-226.64
	Return On Asset	-2.82
	Operating Margin	(45.78) %
	Number Of Shares Shorted	70
	Revenue	1.08 M
	EBITDA	(20.03 M)
	Net Income	(20.06 M)
	Cash And Equivalents	2.24 M
	Cash Per Share	1.32 X
	Total Debt	1.03 M
	Current Ratio	0.87 X
	Book Value Per Share	0.17 X
	Cash Flow From Operations	(16.19 M)
	Beta	-0.38
	Market Capitalization	62.76 M
	Total Asset	13.25 M
	Retained Earnings	(83.86 M)
	Working Capital	3.85 M
	Net Asset	13.25 M

About Cyclo Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cyclo Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cyclo Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cyclo Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Cyclo Stock Analysis

When running Cyclo Therapeutics' price analysis, check to measure Cyclo Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclo Therapeutics is operating at the current time. Most of Cyclo Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cyclo Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclo Therapeutics' price. Additionally, you may evaluate how the addition of Cyclo Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC